Reported Earlier, Annexon Spotlights First-in-Class ANX005 Phase 3 Results For GBS And Launches 'Move GBS Forward' Initiative At AAN
Benzinga Newsdesk 1 year ago
News
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time PointsEducational
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
Educational Symposium Focuses on Advancing GBS Care and Role of Classical Complement Pathway
New Disease Education Campaign "Move GBS Forward" Draws Attention to Life-altering Physical and Mental Impact of GBS